Koers CytRx Corporation Nasdaq
Aandelen
US2328286081
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 644K 600K |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -4 mln. -3,73 mln. | Nettowinst (verlies) 2023 | - 0 | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 1,15 mln. 1,07 mln. | Nettoliquiditeiten 2023 | 2,04 mln. 1,9 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-1,05
x | K/w-verhouding 2023 |
1,91
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,44% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Snowdy
CEO | Chief Executive Officer | 55 | 10-01-22 |
John Caloz
DFI | Director of Finance/CFO | 72 | 01-10-07 |
Cristina Newman
SEC | Corporate Secretary | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Simpson
CHM | Chairman | 55 | 29-07-21 |
Cary Claiborne
BRD | Director/Board Member | 64 | 27-07-22 |
Joel Caldwell
BRD | Director/Board Member | 69 | 12-07-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,28% | 42,68 mld. | |
-3,99% | 42,4 mld. | |
+45,32% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+6,36% | 24,94 mld. | |
-21,47% | 18,96 mld. | |
+27,58% | 12,3 mld. | |
-2,75% | 11,95 mld. | |
-2,02% | 11,55 mld. |